Evidence map›Paper›PMID 40950476›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Enhancer-targeting CRISPR screens at coronary artery disease loci suggest shared mechanisms of disease risk.

Markus Ramste, Chad Weldy, Soumya Kundu, Quanyi Zhao, Daniel Li, Kayla Brand, Disha Sharma, Amanda Ramste, Evelyn Jagoda, Judhajeet Ray and 14 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Markus RamsteDivision of Cardiovascular Medicine, Stanford, CA; 94305.
Chad WeldyDivision of Cardiovascular Medicine, Stanford, CA; 94305.ORCID 0000-0003-4652-6422
Soumya KunduDepartment of Genetics, Stanford, CA; 94305.
Quanyi ZhaoDivision of Cardiovascular Medicine, Stanford, CA; 94305.
Daniel LiDivision of Cardiovascular Medicine, Stanford, CA; 94305.
Kayla BrandDepartment of Genetics, Stanford, CA; 94305.
Disha SharmaDivision of Cardiovascular Medicine, Stanford, CA; 94305.
Amanda RamsteDivision of Cardiovascular Medicine, Stanford, CA; 94305.
Evelyn JagodaThe Novo Nordisk Foundation Center for Genomic Mechanisms of Disease, Broad Institute of MIT and Harvard, Cambridge, MA.
Judhajeet RayThe Novo Nordisk Foundation Center for Genomic Mechanisms of Disease, Broad Institute of MIT and Harvard, Cambridge, MA.
Roxanne Diaz CaceresDivision of Cardiovascular Medicine, Stanford, CA; 94305.
James GalanteDepartment of Genetics, Stanford, CA; 94305.
Andreas R GschwindDepartment of Genetics, Stanford, CA; 94305.
Nuutti LahtinenWihuri Research Institute, University of Helsinki, Washington University School of Medicine, Saint Louis, MO, 63110.
Trieu NguyenDivision of Cardiovascular Medicine, Stanford, CA; 94305.
Junedh M AmruteDivision of Cardiology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO, 63110.ORCID 0000-0002-6851-0168
Chong Yong ParkDivision of Cardiovascular Medicine, Stanford, CA; 94305.
Juyong Brian KimDivision of Cardiovascular Medicine, Stanford, CA; 94305.
Minna U KaikkonenA. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.ORCID 0000-0001-6294-0979
Nathan O StitzielDivision of Cardiology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO, 63110.ORCID 0000-0002-4963-8211
Lars SteinmetzDepartment of Genetics, Stanford, CA; 94305.
Anshul KundajeDepartment of Genetics, Stanford, CA; 94305.
Jesse M EngreitzDepartment of Genetics, Stanford, CA; 94305.ORCID 0000-0002-5754-1719
Thomas QuertermousDivision of Cardiovascular Medicine, Stanford, CA; 94305.ORCID 0000-0002-7645-9067

Funding

Stanford Center for Connecting DNA Variants to Function and PhenotypeUM1HG011972 · NHGRI · STANFORD UNIVERSITY · PI JESSE M ENGREITZ, THOMAS QUERTERMOUS · 2021 to 2026
$10.5M
Scientific Core: Perturb-seq library generation, sequencing, and data analysisP01HL180323 · NHLBI · STANFORD UNIVERSITY · PI THOMAS QUERTERMOUS · 2025 to 2026
$7.1M
Causal variant association mechanisms in TCF21 binding coronary disease lociR01HL134817 · NHLBI · STANFORD UNIVERSITY · PI THOMAS QUERTERMOUS · 2017 to 2026
$6.2M
The SMAD3 signaling network in coronary artery disease riskR01HL139478 · NHLBI · STANFORD UNIVERSITY · PI THOMAS QUERTERMOUS · 2018 to 2026
$3.7M
Mapping, modeling, and manipulating 3D contacts in vascular cells to connect risk variants to disease genesR01HL159176 · NHLBI · STANFORD UNIVERSITY · PI ENGREITZ, JESSE M · 2022 to 2025
$2.8M
PDGFD regulates a transcriptional network to modulate smooth muscle cell transition and coronary artery disease riskR01HL156846 · NHLBI · STANFORD UNIVERSITY · PI QUERTERMOUS, THOMAS · 2021 to 2024
$2.7M
Molecular mechanisms of vascular calcification and their connection to coronary disease riskR01HL158525 · NHLBI · STANFORD UNIVERSITY · PI QUERTERMOUS, THOMAS · 2022 to 2025
$2.4M
Gene regulatory networks controlling smooth muscle phenotype and vasculardisease riskR01HL171045 · NHLBI · STANFORD UNIVERSITY · PI THOMAS QUERTERMOUS · 2024 to 2026
$2.1M
NHGRI NIH HHS UM1 HG011972NHLBI NIH HHS P01 HL180323NHLBI NIH HHS R01 HL134817NHLBI NIH HHS R01 HL139478NHLBI NIH HHS R01 HL156846NHLBI NIH HHS R01 HL158525NHLBI NIH HHS R01 HL159176NHLBI NIH HHS R01 HL171045
6 · The paper itself

Abstract

To systematically identify causal genetic mechanisms that confer risk for coronary artery disease (CAD) in GWAS loci, we mapped genome-wide variant-to-enhancer-to-gene (V2E2G) links in vascular smooth muscle cells (SMC). Enhancers identified by active chromatin features, and further prioritized by base-resolution deep learning models of chromatin accessibility in 108 CAD loci, were studied with CRISPRi targeting and Direct-Capture Targeted Perturb-seq (DC-TAP-seq) evaluation of 470 genes. Seventy-six V2E2G links were identified for 59 candidate CAD genes representing gene programs including epithelial-mesenchymal transformation, ubiquitination, and protein folding as well as BMP and TGFB signaling. Similar methods employed with an independent focused screen targeting one candidate locus at 9p21.3 identified 10 enhancers regulating expression of multiple genes at this location. Detailed molecular studies revealed that two enhancers mediating transcription factor binding and transcriptional regulation contribute to ancestry-specific and sex-specific risk for CAD and the surrogate biomarker vascular calcification. Together, these studies advance our identification of GWAS CAD V2E2G links across the genome, and specific mechanisms of risk at the complex 9p21.3 locus.

Identifiers

PMID40950476
PMCPMC12424881

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.